Dr. Sundar Jagannath: Why a Myeloma Cure is Now Within Reach

The Case for Myeloma Cure

• 💡 Dr. Jagannath passionately asserts that multiple myeloma is now a curable cancer, challenging the traditional view of it as a chronic, incurable disease.
• 🎯 A clear definition of cure is crucial for patients to feel hope, for physicians to adopt a proactive approach and utilize the latest developments, for pharma to invest in new drugs and clinical trials, and for regulatory agencies to approve treatments earlier.

Defining "Cure" and "Remission"

• 🔑 A cure is defined as no trace of cancer for five or more years without any ongoing treatment, similar to other cancers like breast cancer or lymphoma.
• 🔬 Complete remission, the first step to cure, requires no detectable cancer in the blood or urine (using advanced technologies like mass spectrometry).
• ✅ It also necessitates no measurable residual disease (MRD negative) in the bone marrow (less than one cancer cell per million, detectable by FDA-approved technologies like ClonoSEQ) and no detectable cancer on functional imaging (PET CT or whole body MRI) anywhere in the body.

Clinical Evidence of Cure

• 📊 Evidence from the CARTITUDE-1 trial, conducted in 2018-2019, showed that one-third of patients were progression-free at 5 years without maintenance therapy.
• 🔬 Specifically, 12 patients at Dr. Jagannath's center met the full cure criteria, demonstrating no trace of cancer for five years through annual blood tests, bone marrow MRD analysis, and PET CT scans, all without ongoing treatment.

Advanced Treatment Modalities

• 🚀 Significant advancements are rapidly emerging, including bispecific and trispecific antibodies (e.g., targeting BCMA, GPRC5D, CD3) that show high response rates.
• 🧪 Innovative CAR-T cell therapies are also in development, such as those delivered via simple IV injection, allogeneic CAR-T cells from healthy donors, and multi-target CAR-T cells, offering dramatic clinical improvements.

Patient Outlook and Future Hope

• 💬 Dr. Jagannath encourages physicians to treat patients with a curative intent and offer the best available clinical trials and options.
• 🌱 Patients should be assured that they will live longer and that the goal is a cure, with effective treatment options available even if cancer recurs, including four-drug regimens and earlier CAR-T integration. The future for myeloma patients is bright.